Bridged Bicyclo Compounds, Heterocyclic
"Bridged Bicyclo Compounds, Heterocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds that contain two rings that share two non-adjacent atoms in common.
| Descriptor ID |
D019086
|
| MeSH Number(s) |
D03.605.084
|
| Concept/Terms |
Bridged Bicyclo Compounds, Heterocyclic- Bridged Bicyclo Compounds, Heterocyclic
- Bicyclo Compounds, Heterocyclic
- Heterocyclic Bicyclo Compounds
- Bicyclic Heterocyclic Compounds
- Heterocyclic Compounds, Bicyclic
- Heterocyclic Cpds, Bicyclic
- Bicyclic Heterocyclic Cpds
|
Below are MeSH descriptors whose meaning is more general than "Bridged Bicyclo Compounds, Heterocyclic".
Below are MeSH descriptors whose meaning is more specific than "Bridged Bicyclo Compounds, Heterocyclic".
This graph shows the total number of publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in this website by year, and whether "Bridged Bicyclo Compounds, Heterocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 5 | 5 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 3 | 2 | 5 |
| 2025 | 2 | 3 | 5 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in Profiles.
-
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia. Hematol Oncol. 2026 May; 44(3):e70198.
-
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenstr?m Macroglobulinemia. Am J Hematol. 2026 Jun; 101(6):1255-1263.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
Dinaciclib improves treatment response in chemoresistant hepatoblastoma. Sci Rep. 2025 Dec 05; 16(1):1410.
-
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
-
BCL-2 inhibition in Waldenstr?m macroglobulinaemia and marginal zone lymphoma. Br J Haematol. 2025 Dec; 207(6):2261-2269.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.
-
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenstr?m macroglobulinaemia. Br J Haematol. 2025 Jun; 206(6):1604-1614.
-
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
-
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.